by Peter Ciszewski | Dec 23, 2021
Arnon Kater, MD, PhD, Professor of Internal Medicine at the University of Amsterdam discusses new data from the GLOW study of ibrutinib plus venetoclax (I+V) in elderly or unfit chronic lymphocytic leukemia (CLL) patients. The data were recently presented at...
by Peter Ciszewski | Dec 20, 2021
The U.S. Food and Drug Administration (FDA) has approved Vygart (efgartigimod alfa) for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Myasthenia gravis is a chronic autoimmune...
by Peter Ciszewski | Dec 17, 2021
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, discusses 2-year results from the CARTITUDE-1 study evaluating cilta-cel in heavily pre-treated, relapsed/refractory multiple myeloma patients. Multiple myeloma is a blood cancer...
by Peter Ciszewski | Dec 16, 2021
Paolo Ghia, MD, PhD, Professor at the Università Vita-Salute San Raffaele, Milan, Italy, discusses the updated, long-term data from the phase 2 CAPTIVATE study. This study evaluated ibrutinib plus venetoclax as a first-line treatment for chronic lymphocytic...
by Peter Ciszewski | Dec 16, 2021
Paula Rodriguez-Otero, MD, from the University of Navarra, discusses the TRiMM-2 study of teclistamab and talquetamab in combination with daratumumab in the treatment of relapsed/refractory multiple myeloma. Results from this study were recently presented in...
